FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.

被引：0
|
作者：
Deng, Yanhong [1 ]
Hu, Huabin [1 ]
Liu, Guanjian [1 ]
Cai, Yue [1 ]
Zhang, Jianwei [1 ]
Huang, Meijin [1 ]
Wang, Lei [1 ]
Ping, Lan [1 ]
Wang, Jianping [1 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps3624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3624
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [2] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [3] Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation
    Rossi, Luigi
    Veltri, Enzo
    Zullo, Angelo
    Zoratto, Federica
    Colonna, Maria
    Longo, Flavia
    Mottolese, Marcella
    Giannarelli, Diana
    Ruco, Luigi
    Marchetti, Paolo
    Romiti, Adriana
    Barucca, Viola
    Giannini, Giuseppe
    Bianchi, Loredana
    Tomao, Silverio
    ONCOTARGETS AND THERAPY, 2013, 6 : 1761 - 1769
  • [4] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [5] FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] REINTRODUCTION OF FOLFOXIRI TREATMENT IN METASTATIC COLORECTAL CANCER PATIENTS PROGRESSED AFTER FIRST-LINE FOLFOXIRI
    Baldi, Giacomo Giulio
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Stasi, Irene
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Pfanner, Elisabetta
    Brunetti, Isa Maura
    Di Donato, Samantha
    Caponi, Sara
    Allegrini, Giacomo
    Antonuzzo, Andrea
    Ricci, Sergio
    Andreuccetti, Michele
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2009, 20
  • [7] Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI
    Vasile, E.
    Masi, G.
    Loupakis, F.
    Cupini, S.
    Baldi, G. G.
    Salvatore, L.
    Fornaro, L.
    Pfanner, E.
    Ricci, S.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [8] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [9] Folfoxiri with or without cetuximab as first-line treatment of patients with non-resectable liver, only metastatic colorectal cancer and KRAS/NRAS wild type (FOCULM study)
    Deng, Yanhong
    Wang, Lei
    Liu, Guanjian
    Hu, Huabin
    Cai, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone
    Rizzo, Alessandro
    Palloni, Andrea
    Frega, Giorgio
    Abbati, Francesca
    De Lorenzo, Stefania
    Brocchi, Stefano
    Brandi, Giovanni
    ANTI-CANCER DRUGS, 2019, 30 (04) : 428 - 430
12345